生产企业：Novartis
Remibrutinib (Rhapsido) is approved as an oral therapy for the treatment of chronic spontaneous urticaria (CSU). It is also under Phase 3 clinical investigation for the treatment of multiple sclerosis (MS); a Phase 3 trial met its primary endpoint by significantly reducing relapses compared with teriflunomide.
